ProfileGDS5678 / 1428924_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 66% 67% 65% 69% 72% 66% 67% 66% 65% 69% 67% 68% 66% 67% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.0022866
GSM967853U87-EV human glioblastoma xenograft - Control 24.0804967
GSM967854U87-EV human glioblastoma xenograft - Control 33.9290565
GSM967855U87-EV human glioblastoma xenograft - Control 44.3033869
GSM967856U87-EV human glioblastoma xenograft - Control 54.5813972
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.0159366
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0899567
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.02866
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.9144565
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.2797569
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.0992567
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.1258468
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.0012266
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.0661867